actinium has been researched along with Liver Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baum, RP; Kulkarni, HR; Zhang, J | 1 |
| Baidoo, KE; Bell, MM; Choyke, PL; Escorcia, FE; Gutsche, NT; Kelada, OJ; King, AP | 1 |
2 other study(ies) available for actinium and Liver Neoplasms
| Article | Year |
|---|---|
Peptide Receptor Radionuclide Therapy Using 225Ac-DOTATOC Achieves Partial Remission in a Patient With Progressive Neuroendocrine Liver Metastases After Repeated β-Emitter Peptide Receptor Radionuclide Therapy.
Topics: Actinium; Aged; Beta Particles; Disease Progression; Female; Humans; Liver Neoplasms; Neuroendocrine Tumors; Octreotide; Receptors, Peptide; Treatment Outcome | 2020 |
Glypican-3-Targeted Alpha Particle Therapy for Hepatocellular Carcinoma.
Topics: Actinium; Alpha Particles; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Carcinoma, Hepatocellular; Glypicans; Humans; Kidney; Liver; Liver Neoplasms; Mice; Molecular Targeted Therapy; Tissue Distribution | 2020 |